Last reviewed 2026-04-20 · How we verify

Onoact (LANDIOLOL)

Onoact works by blocking the beta-1 adrenergic receptor, which helps to slow down abnormal heart rhythms.

At a glance

Mechanism of action

Think of your heart like a racing car engine. When the beta-1 adrenergic receptor is stimulated, it's like stepping on the gas pedal, making the engine rev faster. Onoact blocks this receptor, so the engine doesn't rev as fast, helping to slow down abnormal heart rhythms.

Approved indications

• Atrial fibrillation
• Atrial flutter
• Hemodynamically unstable ventricular tachycardia
• Sinus tachycardia
• Supraventricular tachycardia
• Tachyarrhythmia
• Ventricular fibrillation

Common side effects

No common side effects on file.

Key clinical trials

• Landiolol in Mitral Valve Surgery (PHASE4)
• Impact of Cardio-Selective Beta-Blockers on Infarct Size After Acute Myocardial Infarction
• LANdiolol to Avoid TAchycardia in Patients at Risk for Cardiovascular Events Undergoing Major Non-cardiac Surgery (PHASE4)
• Comparison of Landiolol Versus Standard of Care for Prevention of Mortality in Patients Hospitalized for a Septic Shock With Hypercontractility (PHASE3)
• Landiolol in Postoperative Atrial Fibrillation (PHASE3)
• LANdiolol MIcrocirculatory Effects During Septic chOc (MILANOS) (PHASE3)
• Prevention of Atrial Fibrillation by Low-dose Landiolol Administration After Cardiac Surgery (PHASE3)
• Beta-blockade With Landiolol in Out-of-hospital Cardiac Arrest (PHASE1,PHASE2)

Patents

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

• Onoact CI brief — competitive landscape report
• Onoact updates RSS · CI watch RSS
• Aop Hlth Us portfolio CI